OAKLAND, Calif., March 30 (Reuters) - A U.S. jury awarded GlaxoSmithKline no damages on its antitrust claims against Abbott Laboratories over allegations of unfair HIV drug pricing, according to an Abbott representative.
Glaxo accused Abbott of improperly hiking the price of one drug to help it preserve sales growth of one of its other HIV blockbusters.
The case had been in trial in an Oakland, California federal court. The jury awarded Glaxo $3.4 million on the remainder of its legal claims, Abbott spokeswoman Adelle Infante said.
(Reporting by Dan Levine; Editing by Richard Chang)
(dan.levine@thomsonreuters.com; +1 415 348-4726)
Keywords: ABBOTT GLAXO/LAWSUIT
COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Glaxo accused Abbott of improperly hiking the price of one drug to help it preserve sales growth of one of its other HIV blockbusters.
The case had been in trial in an Oakland, California federal court. The jury awarded Glaxo $3.4 million on the remainder of its legal claims, Abbott spokeswoman Adelle Infante said.
(Reporting by Dan Levine; Editing by Richard Chang)
(dan.levine@thomsonreuters.com; +1 415 348-4726)
Keywords: ABBOTT GLAXO/LAWSUIT
COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.